ATE424209T1 - Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung - Google Patents
Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlungInfo
- Publication number
- ATE424209T1 ATE424209T1 AT03782745T AT03782745T ATE424209T1 AT E424209 T1 ATE424209 T1 AT E424209T1 AT 03782745 T AT03782745 T AT 03782745T AT 03782745 T AT03782745 T AT 03782745T AT E424209 T1 ATE424209 T1 AT E424209T1
- Authority
- AT
- Austria
- Prior art keywords
- gnrh
- luteal phase
- support
- phase during
- gnrh agonists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 3
- 230000036512 infertility Effects 0.000 title abstract 3
- 230000029849 luteinization Effects 0.000 title abstract 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 title 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 title 1
- 208000000509 infertility Diseases 0.000 title 1
- 231100000535 infertility Toxicity 0.000 title 1
- 108700012941 GNRH1 Proteins 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000601 hypothalamic hormone Substances 0.000 abstract 1
- 229940043650 hypothalamic hormone Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 230000016087 ovulation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2093—Leukaemia inhibitory factor [LIF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0216810A FR2849380A1 (fr) | 2002-12-27 | 2002-12-27 | NOUVELLE UTILISATION D'UN AGONISTE DU GnRH |
US44846803P | 2003-02-21 | 2003-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE424209T1 true ATE424209T1 (de) | 2009-03-15 |
Family
ID=32683902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03782745T ATE424209T1 (de) | 2002-12-27 | 2003-12-29 | Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung |
Country Status (9)
Country | Link |
---|---|
US (1) | US7671027B2 (de) |
EP (1) | EP1578427B1 (de) |
AT (1) | ATE424209T1 (de) |
AU (1) | AU2003290383A1 (de) |
DE (1) | DE60326490D1 (de) |
DK (1) | DK1578427T3 (de) |
ES (1) | ES2323693T3 (de) |
FR (1) | FR2849380A1 (de) |
WO (1) | WO2004058269A1 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0307777D0 (en) | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
CA2623558A1 (en) | 2005-09-27 | 2007-04-05 | Myriad Genetics, Inc. | Pyrrole derivatives as therapeutic compounds |
US20150273020A1 (en) * | 2007-05-11 | 2015-10-01 | Lori R. Bernstein | Hormone Normalization Therapy and Uses Therefor |
SI2359807T1 (sl) | 2008-02-04 | 2017-10-30 | Ferring B.V. | Monolitni intravaginalni obroč, ki vsebuje progesteron ter postopki za njegovo izdelavo in uporabo |
FR2942409B1 (fr) * | 2009-02-20 | 2013-07-26 | Natacha Voillot | Composition pharmaceutique pour la prevention des avortements a repetition. |
AU2010246918A1 (en) * | 2009-05-14 | 2011-12-01 | Adelaide Research & Innovation Pty Ltd | Methods for the collection and maturation of oocytes |
WO2011076117A1 (zh) | 2009-12-22 | 2011-06-30 | 上海天伟生物制药有限公司 | 绝经期促性腺素组合物 |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150272622A1 (en) | 2011-12-22 | 2015-10-01 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
US9216037B2 (en) | 2013-06-21 | 2015-12-22 | Previvo Genetics, Llc | Uterine lavage for embryo retrieval |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
KR20170040209A (ko) | 2014-07-29 | 2017-04-12 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 경피 크림 |
PL3037101T3 (pl) * | 2014-12-22 | 2019-06-28 | Ferring B.V. | Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US11773368B2 (en) * | 2015-09-17 | 2023-10-03 | National Agriculture And Food Research Organization | Culture method for differentiating primordial germ cells into functionally mature oocytes |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
CN112352045B (zh) * | 2018-06-21 | 2023-10-20 | 国立大学法人九州大学 | 在体外将原始生殖细胞分化为原始卵泡的方法 |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5538948A (en) * | 1987-01-30 | 1996-07-23 | Novo Nordisk A/S | Method for treating infertility comprising administering GnRH analog, gonadotrophins, and growth hormone |
US6489288B1 (en) * | 1990-03-16 | 2002-12-03 | Applied Research Systems Ars Holding | Treatment of polycystic ovarian disease |
FR2713933B1 (fr) * | 1993-12-16 | 1996-02-02 | Rhone Merieux | Méthode de superovulation des femelles bovines, méthode de mise en anoestrus et kit approprié. |
-
2002
- 2002-12-27 FR FR0216810A patent/FR2849380A1/fr active Pending
-
2003
- 2003-12-29 US US10/540,228 patent/US7671027B2/en not_active Expired - Fee Related
- 2003-12-29 AT AT03782745T patent/ATE424209T1/de active
- 2003-12-29 WO PCT/IB2003/006205 patent/WO2004058269A1/en not_active Application Discontinuation
- 2003-12-29 AU AU2003290383A patent/AU2003290383A1/en not_active Abandoned
- 2003-12-29 EP EP03782745A patent/EP1578427B1/de not_active Expired - Lifetime
- 2003-12-29 DE DE60326490T patent/DE60326490D1/de not_active Expired - Lifetime
- 2003-12-29 DK DK03782745T patent/DK1578427T3/da active
- 2003-12-29 ES ES03782745T patent/ES2323693T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20060069031A1 (en) | 2006-03-30 |
EP1578427B1 (de) | 2009-03-04 |
ES2323693T3 (es) | 2009-07-23 |
US7671027B2 (en) | 2010-03-02 |
WO2004058269A1 (en) | 2004-07-15 |
FR2849380A1 (fr) | 2004-07-02 |
AU2003290383A1 (en) | 2004-07-22 |
DE60326490D1 (de) | 2009-04-16 |
DK1578427T3 (da) | 2009-06-29 |
EP1578427A1 (de) | 2005-09-28 |
WO2004058269A9 (en) | 2004-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE424209T1 (de) | Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung | |
BRPI0409128A (pt) | uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável | |
EA200200208A1 (ru) | Синергитическая композиция | |
CR7716A (es) | Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor | |
ECSP045520A (es) | Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos | |
DE69027865T2 (de) | ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN | |
AR005987A1 (es) | Terapia combinada para la osteoporosis | |
Jimenez-Krassel et al. | Evidence for a negative intrafollicular role for inhibin in regulation of estradiol production by granulosa cells | |
HUP0200079A2 (hu) | A terméketlenség kezelése | |
WO2001074839A3 (en) | Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use | |
ATE412412T1 (de) | Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1 -pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata-oder gebahrmutterkrebs | |
DE60039878D1 (de) | XENON ALS NMDA-ANTOGONIST zur Neuroprotektion | |
ATE399002T1 (de) | Pharmazeutische zubereitungen für die behandlung von läsionen der haut und schleimhäute und diese verwendende verfahren und kits | |
DK1202727T3 (da) | Anvendelse af agonister af GABAB-receptorer og farmaceutisk acceptable derivater deraf til behandling for at opnå fortsat nikotinafholdenhed hos nikotinafhængige patienter | |
JP2003528919A5 (de) | ||
PE20050665A1 (es) | ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL | |
BG101126A (en) | The use of muramylpeptide compounds | |
EA200200943A1 (ru) | Гормональная терапия рака молочной железы | |
DK1680139T3 (da) | Anvendelse af somatostatin eller et derivat heraf til fremstilling af et lægemiddel beregnet til at regulere ovarifollikelreserven hos ikke-menopausale kvinder | |
AR032390A1 (es) | Uso de gestagenos para inhibir la maduracion acelerada del endometrio durante el tratamiento de la infertilidad | |
BR0111546A (pt) | Produto combinado, método para a produção de um kit de partes, kit de partes, método de tratamento de uma condição, usos de um produto combinado ou de um kit de partes, e, de um melagatrano e de um inibidor de fator viia, ou de um derivado farmaceuticamente aceitável dos mesmos | |
ATE440601T1 (de) | Hydroxypyridinone zur lokalen behandlung von hautmikrozirulationsstírungen | |
DK384086A (da) | Antigestagener til forskydning af den endometriale modning | |
DK0907737T3 (da) | IL-6-mutein | |
DE60045555D1 (de) | Apparat zur verringerung des embolierisikos während der behandlung von erkrankungen der kopfschlagader |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1578427 Country of ref document: EP |